AbbVie Inc.’s blockbuster cancer treatment Imbruvica in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
Janssen Pharmaceutical and Apple have teamed up to determine if a new app for the Apple Watch – which has a built-in electrocardiogram – can improve the health of more than 30 million people with atrial fibrillation (AFib), a condition that can lead to stroke and other potentially devastating complications.
JLL’s life sciences experts anticipate that Big Pharma during 2019 will adopt agile real estate strategies and more entrepreneurial approaches to reinvent R&D and compete with smaller enterprises that are doubling down on product innovation and delivery.
Researchers at New York University School of Medicine and Janssen Research & Development, a Johnson & Johnson company, developed a new class of engineered proteins that may help fight the bacteria that cause Staph infections.
Researchers at Tufts University and Yale University School Of Medicine identified a new molecular mechanism that could restore plasticity in aged brains.
Scientists unveiled what they say is an ideal diet for the health of the planet and its people.
Close to 44 percent of U.S. physicians are burned out, and 15 percent are depressed and thinking about suicide, according to a survey conducted by Medscape.
Merck & Co. released data from KEYNOTE-181, a Phase III trial of Keytruda as a monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma.
Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.
Artificial intelligence technology has an established home in drug design for many developers. Now, researchers are seeing AI technology as a potential tool in driving therapeutic choices in the treatment of ovarian cancer.